Quanterix Corporation · NASDAQ:QTRX
Quanterix — Q1 2019 Earnings Presentation
35 slides from Quanterix's earnings presentation, 2019
Slide 1: Quanterix: The Science of Precision Health
Quanterix’ The Science of Precision Health
Slide 2: Forward-Looking Statements
Forward-Looking Statements Quanterix The Science of Precision Health This presentation contains “forward-looking” statements that are based on our beliefs and assumptions and on information available to us as of the date of this presentation. Forward-looking statements include all statements that ar
Slide 3: Today's Agenda
Today's Agenda Quanterix The Science of Precision Health |. Strategic and Financial Progress — Kevin Hrusovsky — Chairman, CEO i. Q1 Highlights ii. 2019 Goals & Priorities iii. Transforming Medicine: Neurology Momentum Update ||. Financial Report —- Amol Chaubal — CFO \I!. Summary of QTRX Opportunit
Slide 4: Massive Market Opportunity, Disruptive Technology and Continued Growth in Revenues & Publications
Massive Market Opportunity, Disruptive Technology and Continued Growth in Revenues & Publications Quanterix The Science of Precision Health Neuro + Oncology Total QTRX Revenue Growth Research: Today ma Market: $1B to $8B Products to Pharma Services Res tees 465% | $ 37.6 Diagnostics: 2020+ Market: $
Slide 5: Q1 2019 Growth Led by Consumables and Instruments
Q1 2019 Growth Led by Consumables and Instruments Quanterix The Science of Precision Health —_—_— {$ in millions) = 64% Growth 28% _ Instruments (+708) Product Growth = High margin mix accelerating a Qi'19 cr. +124% | 101% Consumables Revenue ai = Consumables growth +124%; GM 48.2%, +450bp 23% Servi
Slide 6: Scientific Research is Driving Brand Awareness, Performance and Utilization
Scientific Research is Driving Brand Awareness, Performance and Utilization Quanterix The Science of Precision Health PUBLICATIONS** MARKERS** ACCELERATOR INSTRUMENTS* CONSUMABLES Other Oncology | | Neurology 506 409 135 129 206 80 104 sc 192 53 30 cs eo are 2015 2016 2017 2018 2019 133 190 259 286
Slide 7: Q1 2019 Growth Stratification
Q1 2019 Growth Stratification a lerterb: ‘The Science of Precision Health TH Quanterix 47%Custo mera Diseases Growth Growth Growth ul NA 193% al Pharma/Biotech CRO +126% Neurology a9 95%) Europe +96% Academia +79% Oncology +86% Cardiology -82% Asia +161% ID +91%
Slide 8: 2019 Targets & Growth Catalysts On or Ahead of Schedule
2019 Targets & Growth Catalysts On or Ahead of Schedule Quanterix The Science of Precision Health Neurology Oncology High double digit 3x Neuro growth New entrant <10% penetrated ad Launch SP-X, _ _ , + 100x more sensitivity Add 25 assays, CorPlex Assays — =xplore IVD direct /- targeted by 2021 YE l
Slide 9: Transforming Medicine with Digital Biomarkers
Transforming Medicine with Digital Biomarkers Quanterix The Science of Precision Health Today: Invasive and Late Tomorrow: Non-invasive and Early
Slide 10: Simoa Sees Health to Disease Continuum
Simoa Sees Health to Disease Continuum biomarker ees O centration . Biopsy, spinal tap or other invasive jprocedures Current letection limit New letection blood limit || emus | urine Placement of disease categories is for illustration purposes only anterix The Science of Precision Health sickness be
Slide 11: Biomarker Disruption - Applications
BIOMARKER DISRUPTION - Applications a Quanterix Science of Precision Health 30 pubs 170 pubs 130 pubs 36 markers 50 rakes: 95 ene Neurology Cardiology ID, Inflammation TOTALS: Other* Oncology DEATHS / YR 9MM 18MM 7MM 145MM ~SOMM ww cost $350B $270B $470B $140B $1.3T BIOMARKER $25B $6B — $98 — $38B M
Slide 12: Quanterix Product Offerings
Quanterix P uct Offerings Quanterix ‘The Science of Precision Health HD-1/ Floor-standing integrated automated system Assay prep and detection (sample->answer) 400+ publications SR-X Benchtop semi- automated assay prep using standardized benchtop devices Quanterix TM Ultra-sensitive Simoa planar ass
Slide 13: Simoa: Technology and Instrumentation
Simoa: Technology and Instrumentation ienterix The Science of Precision Health 3'¢ Generation 4th Generation Quanterix — 100x Sensitivity Target by 2021 Ss @ g il maa HD-1 SR-X HD-X SP-X ; (2014) (2018) (2H 19) (1H 19) 3 simOa fo} 2 la 3 =I 5 ml iE 000 2 eats 24 Generation Luminex. 1** Generation Be
Slide 14: Competitive Landscape
Competitive Landscap Quanterix The Science of Precision Health . penere : Quanterix Luminex. Singulex 060 i © Erenna Electrochemi Technology Immunoassay Immunoassay luminescence Sensitivity a a a) onan ° 0 8 °@ Automation & Ease of Use Pes ° © 8 e@ E won | © 0 8 °o H H Ww © © @ 0 H | ct o 0 0 oO s 1
Slide 15: We are Addressing a Significant Unmet Need in Drug Development
We are Addressing a Significant Unmet Need in Drug Development FDA Announces Office of Drug Evaluation Science - ODES Quanterix The Science of Precision Health DRUG PERFORMANCE PROBABILITY OF DRUG APPROVAL VAI TION OF SIMOA IMPACT Simoa’S at CROs _ Trials atQuanterix 32 TOXICITY Adverse drug events
Slide 16: Business-Favorable Changes in IVD Regulatory Climate
Business-Favorable C hanges in IVD Regulatory Climate Quanterix ‘The Science of Precision Health Early Alzheimer’s Disease: Developing Drugs for Treatment Guidance for Industry FDA INITIATIVE... AT IT MEANS FOR QTRX. Recognizes the criticality of Encourages biopharma to using biomarkers. identify/in
Slide 17: Blue Chip Customers
Blue Chip Customers Quanterix The Science of Precision Health Research Institutions Biopharma Ly * Biogen MYRIAD@RBM. > merck 2, fj) Boehringer won Qoewn Yel orgien ii ill) Ingetheim @® cross a Institut Pasteur <a ANIGEN ae 2014 17
Slide 18: Blue Chip Customers
Blue Chip Customers Quanterix The Science of Precision Health Research Institutions Biopharma Pa Ue GORE ar La, GD Biogen abbvie Genentech ADX 4B Bristol-Myers Squibb MYRIADORBM. § § BLT ~svsmex zoetis @ FRONTAGE ¥ BioChek en ease P Scrum QP MERK ine CoN MTERLESTUAL Laon @* @ ‘aaruus universitet UNI
Slide 19: Neurology biomarkers
Quanterix The Science of Precision Health DENDRITES NSE UCH-L1 N EU RON SYNAPSES AXON SVA2,synaptdtagmi —3aDan..~ JY =J a MYELIN Amyloids SS SHEATH GFAP —— - MICROGLIAL 51008 CELLS ASTROCYTES CAPILLARY Grekines BLOOD Autoantibodies VESSEL 19
Slide 20: Neurology Momentum Fueling Growth
Neurology Momentum Fueling Growth and Fu Quanterix The Science of Precision Health Neurology Momentum 0, CAGR 139% CAGR 67% 200 as CAGR 67% 100 50 | i a | ull 8 Pubs Markers Instruments 2015 2016 m2017 m2018 vi, tay Bloomberg ili a Strongest growth in neurology RUO franchise with accelerating public
Slide 21: NF-L Rapidly Expanding as Best In Class Neuro Biomarker
NF-L Rapidly Expanding as Best In Class Neuro Biomarker Quanterix The Science of Precision Health RESEARCH PUBLICATIONS ON NFL 160 7 “? Three shots on goal: 120 4 46 active clinical wt MS, TBI and Alzheimer’s trials using SNL PubMed Citations * Biogen 1) NOVARTIS 4 SANOFI 2000 2002 2004 2006 2008 20
Slide 22: Emerging Clinical Biomarker: Neurofilament Light (NfL)
Emerging Clinical Biomarker: Neurofilament Light (Nf Quanterix The Science of Precision Health NFL PUBLICATIONS WW DISEASE INCIDENCE (MILLIONS) 2015 2016 2017 2018 15 10 Ce vw yy 0 —_ a_i * Parkinsons FID Alzheimers STUDIES CONFIRM NFL CLINICAL UTILITY: MULTIPLE SCLEROSIS: + Disease activity monitor
Slide 23: Neurology
eurology' Blood neurofilament light chain as a biomarker of MS disease activity and treatment response Jens Kuhle, MD,* Harald Kropshofer, PhD,* Dieter A. Haering, PhD, Uma Kundu, MPharm, Rolf Meinert, PhD, Christian Barro, MD, Frank Dahike, MD, Davorka Tomic, PhD, David Leppert, MD, and Ludwig Kapp
Slide 24: Simoa NfL Meeting Abstracts & Presentations
NEL Simoa NFL 45 Meeting Abstracts & Presentations QF 40 : y Tian in : 35 ia =: Natalizumab Reduces Serum Concentrations of \ 30 Neurofilament Light Chain in Secondary Progressive Multiple Sclerosis Patients From the Phase 3 25 ASCEND Study Te ay = 20 = Long-term Effect of Fingolimod in Reducing Blo
Slide 25: Simoa NfL Multicenter Analytical Validation
Simoa NfL Multicenter Analytical Validation - 17 sites across Europe and North America Quanterix The Science of Precision Health Location Tavestigator Study Site 1 Ansterdam Dr Charlotte Neurochemistry Laboratory, Amsterdam University Zz Barcelona Dr. Manuel Laboratori de Neuroinmmnologia Clinica Ce
Slide 26: NFL Normative and MS Study - Swiss Multiple Sclerosis Registry
NFL Normative and MS Study - Swiss Multiple Sclerosis Registry Quanterix The Science of Precision Health 5|- Universitatsspital “| | Basel ia Jens Kuhle, MD, PhD, and Prof. David Leppert, 10 collaborating institutions 18,000 samples across demographics (2019) 7,000-8,000 MS samples (2020-2021) po} =
Slide 27: Blood Test May Detect Alzheimer's In Patients Years Before Symptoms Appear
Blood Test May Detect Alzheimer’s In Patients 16 Y. inte Symptoms Appe r of Precision Health LS See ee] Blood test could detect Alzheimer's up to 16 years before symptoms begin, Serum neurofilament dynamics predicts vf f J study says neurodegeneration and clinical progression in a Sopot Bes A ht 2 0
Slide 28: Nature publication on serum neurofilament in presymptomatic Alzheimer's
Oliver Preische1,2,21, Stephanie A. Schultz3.21, Anja Apel1,2.21, Jens Kuhle4, Stephan A. Kaeser1,2, Christian Barro4, Susanne Grabert, Elke Kuder-Buletta 1, Christian nature,, . LaFougere', Christoph Laske't2, Jonathan VogieinS 6, Johannes LevinS 6, Colin L. Masters7, Ralph Marfins8,9, Peter R. Sch
Slide 29: Digital Biomarkers Disruption Paradigm: Alzheimer's Disease Opportunity
Digital Biomarkers Disruption Paradigm: mitenterix Alzheimer’s Disease Opportunity The cence of ection Heh Alzheimer’s disease not Imaging expensive and often Therapies for later stage diagnosed until symptoms not covered disease have limited effectiveness A © _ Detect or screen in Follow on Image o
Slide 30: Taking Aim at Alzheimer's Disease with Simple Blood Tests
Taking Aim at Alzheimer’s Disease with Simple Blood Quanterix The Science of Precision Health ‘Association of Plasma Neurofilament Light =~") With Sudden Progress, Blood AB. ===) Rivals PET at Detecting Amyloid neurodegeneration and clinical progression in presymptomatic Alzheimer's disease +S] Seru
Slide 31: TRACK-TBI and concussion biomarker studies
uanterix ‘The Science of Precision Health National Institute of = Neurological Disorders me P and Stroke S Fr enn ) TRACK -TB1 Trasaring Research and Clinical Koowedge in Traumatic Bria lojory | | w& Statistics Geoff Manley MD PhD Canada UCSF, TRACK-TBI as cn ts otra some Neurofilament light and tau
Slide 32: Ultrasensitive LIF Assay Revealed as Promising Blood Biomarker for Pancreatic Cancer
__ ae Ultrasensitive LIF Assay Revealed as Promising Blood Biomarker # Drug Target for Pancreatic Cancer me ene 1) Science News from research organizations New study targets Achilles' heel of pancreatic cancer, with promising results Researchers discover a potential therapeutic target for deadly can
Slide 33: Q1 2019 Financials
Q1 2019 Financials Quanterix The Science of Precision Health in $m a12019 ff Qi 2018 aided me | 9.5 47 6.1 Product Revenue +4.8 Growth vs. PYR +101% 410% 1 111% 4 3.4 Lab/Services 2.8 25 +0.3 Growth vs. PYR +11% Collaboration - 0.3 -0.3 Instruments Consumables Lab. & Other Services Total Revenue 12.
Slide 34: Poised to Disrupt Healthcare and Create Significant Value
Poised to Disrupt Healthcare and Create Significant Value Quanterix The Science of Precision Health r+) Category-defining; Unrivaled Sensitivity / Technology eo Methodical market penetration strategy to reward investors market C3 ] DNA-— RNA - Protein; Better linked to Disease / Health Quanterix ts
Slide 35: Quanterix in the News — Q1 2019
Quanterix in the News — Q1 2019 Quanterix continued to build awareness for its mission to advance the science of precision health in mainstream press and trade media. PPH 2018 - Amsterdam ABC — Feb 2019 Bloomberg Radio Feb 2019 WCVBTV BOSTON PROMISE OF EARLY CANCER DETECTION AN teil 4 New technology